自体外周血造血干细胞移植与硼替佐米联合地塞米松治疗原发性轻链型淀粉样变性的疗效和安全性比较

目的比较大剂量马法兰预处理的自体外周血造血干细胞移植(auto-PBSCT)与硼替佐米联合地塞米松(VD方案)治疗原发性轻链型淀粉样变性的疗效和安全性。方法回顾性分析2004年9月至2012年9月38例原发性轻链型淀粉样变性患者的临床资料,其中auto-PBSCT组15例,VD组23例。结果所有患者的中位随访时间为34(1~112)个月,auto-PBSCT组为38(5~112)个月,VD组为31(1~108)个月。38例患者中15例(39.5%)获得器官缓解,auto-PBSCT组和VD组器官缓解率差异无统计学意义[33.3%(5/15)对43.5%(10/23),P=0.532],达到器官...

Full description

Saved in:
Bibliographic Details
Published in中华血液学杂志 Vol. 37; no. 4; pp. 283 - 287
Main Author 赵茜 王利平 宋萍 李锋 周小钢 于亚平 安志明 王旭丽 翟勇平
Format Journal Article
LanguageChinese
Published 210002,南京军区南京总医院血液科 2016
Subjects
Online AccessGet full text
ISSN0253-2727
DOI10.3760/cma.j.issn.0253-2727.2016.04.007

Cover

Abstract 目的比较大剂量马法兰预处理的自体外周血造血干细胞移植(auto-PBSCT)与硼替佐米联合地塞米松(VD方案)治疗原发性轻链型淀粉样变性的疗效和安全性。方法回顾性分析2004年9月至2012年9月38例原发性轻链型淀粉样变性患者的临床资料,其中auto-PBSCT组15例,VD组23例。结果所有患者的中位随访时间为34(1~112)个月,auto-PBSCT组为38(5~112)个月,VD组为31(1~108)个月。38例患者中15例(39.5%)获得器官缓解,auto-PBSCT组和VD组器官缓解率差异无统计学意义[33.3%(5/15)对43.5%(10/23),P=0.532],达到器官缓解的中位时间差异有统计学意义[6(3~10)个月对3(1~6)个月,P=0.032]。两组患者的3年总生存率分别为72.0%和66.9%,预期总生存期分别为84.7个月和75.9个月(P=0.683)。auto-PBSCT组Ⅲ/Ⅳ级骨髓抑制(P〈0.001)、发热(P〈0.001)和恶心、呕吐(P=0.006)的发生率高于VD组,而肺感染(P=0.069)、血流感染(P=0.059)的发生率差异无统计学意义(P〉0.05)。结论auto-PBSCT和VD方案治疗原发性轻链型淀粉样变性患者的器官缓解率相当,生存时间无明显差异,但auto-PBSCT组不良反应更多见。
AbstractList 目的比较大剂量马法兰预处理的自体外周血造血干细胞移植(auto-PBSCT)与硼替佐米联合地塞米松(VD方案)治疗原发性轻链型淀粉样变性的疗效和安全性。方法回顾性分析2004年9月至2012年9月38例原发性轻链型淀粉样变性患者的临床资料,其中auto-PBSCT组15例,VD组23例。结果所有患者的中位随访时间为34(1~112)个月,auto-PBSCT组为38(5~112)个月,VD组为31(1~108)个月。38例患者中15例(39.5%)获得器官缓解,auto-PBSCT组和VD组器官缓解率差异无统计学意义[33.3%(5/15)对43.5%(10/23),P=0.532],达到器官缓解的中位时间差异有统计学意义[6(3~10)个月对3(1~6)个月,P=0.032]。两组患者的3年总生存率分别为72.0%和66.9%,预期总生存期分别为84.7个月和75.9个月(P=0.683)。auto-PBSCT组Ⅲ/Ⅳ级骨髓抑制(P〈0.001)、发热(P〈0.001)和恶心、呕吐(P=0.006)的发生率高于VD组,而肺感染(P=0.069)、血流感染(P=0.059)的发生率差异无统计学意义(P〉0.05)。结论auto-PBSCT和VD方案治疗原发性轻链型淀粉样变性患者的器官缓解率相当,生存时间无明显差异,但auto-PBSCT组不良反应更多见。
目的 比较大剂量马法兰预处理的自体外周血造血干细胞移植(auto-PBSCT)与硼替佐米联合地塞米松(VD方案)治疗原发性轻链型淀粉样变性的疗效和安全性.方法 回顾性分析2004年9月至2012年9月38例原发性轻链型淀粉样变性患者的临床资料,其中auto-PBSCT组15例,VD组23例.结果 所有患者的中位随访时间为34(1~112)个月,auto-PBSCT组为38(5~112)个月,VD组为31(1~108)个月.38例患者中15例(39.5%)获得器官缓解,auto-PBSCT组和VD组器官缓解率差异无统计学意义[33.3%(5/15)对43.5%(10/23),P=0.532],达到器官缓解的中位时间差异有统计学意义[6(3~10)个月对3(1~6)个月,P=0.032].两组患者的3年总生存率分别为72.0%和66.9%,预期总生存期分别为84.7个月和75.9个月(P=0.683).auto-PBSCT组Ⅲ/Ⅳ级骨髓抑制(P<0.001)、发热(P<0.001)和恶心、呕吐(P=0.006)的发生率高于VD组,而肺感染(P=0.069)、血流感染(P=0.059)的发生率差异无统计学意义(P>0.05).结论 auto-PBSCT和VD方案治疗原发性轻链型淀粉样变性患者的器官缓解率相当,生存时间无明显差异,但auto-PBSCT组不良反应更多见.
Abstract_FL Objective To explore the feature of primary light chain amyloidosis patients treated with high-dose melphalan with auto peripheral blood stem cell transplantation (auto-PBSCT) and bortezomib plus dexamethasone (VD).Methods Thirty-eight patients diagnosed from September 2004 to September 2012 were analyzed retrospectively,including 15 cases received auto-PBSCT,23 cases exposed with VD.Results The median follow-up duration for the patients was 34 months (range,l-112 months),including auto-PBSCT group of 38 months (range,5-112 months) and VD group of 31 months (range,1-108 months).The organ response rate in all the patients was 39.5% (15/38),and the organ response rate between these two groups has no significant difference [33.3%(5/15) vs 43.5% (10/23),P=0.532].However,the median time of organ response was significant difference [6 (3-10) months vs 3 (1-6) months,respectively (P=0.032)].The 3-year overall survival (OS) rates in the two groups were 72.0% and 66.9%,and their average survival were 84.7 months and 75.9 months,respectively (P=0.683).In the patients with auto-PBSCT,the occurrence of Ⅲ-Ⅳ grade of bone marrow suppression (P < 0.001),fever (P < 0.001),nausea and infection (P=0.006) were obviously higher than those with VD,but there was no statistically significant difference in pulmonary infection (P=0.069) and bloodstream infection (P=0.059).Conclusions The preliminary results have presented that primary light chain amyloidosis patients treated with auto-PBSCT or VD had similar organ response rate and survival.However,more adverse events occurred in the group of auto-PBSCT.
Author 赵茜 王利平 宋萍 李锋 周小钢 于亚平 安志明 王旭丽 翟勇平
AuthorAffiliation 南京军区南京总医院血液科,210002
AuthorAffiliation_xml – name: 210002,南京军区南京总医院血液科
Author_xml – sequence: 1
  fullname: 赵茜 王利平 宋萍 李锋 周小钢 于亚平 安志明 王旭丽 翟勇平
BookMark eNo9kMlKA0EQhvug4PoSHsTLjD3Tne7JUYIbCF5yD51JjyboRDOIyyniEoOaqIkLLtGAoHhwiYcoMfFl0j3jW9iieKmivvqogr8HdLhplwMwZEAdUQKH7Xmmp_Sk57k6NENIM6lJdRMaRIdYh5B2gO5_3gV6PC8FIVZ73A1yQe6h3SyJ2xNxeB9Us1_ZG1XFe81vbAcbFf-uIW_3228Fv_ohLz7bzQP_5TVYL4uDHXH5LKoVNcqrlqw1_JNTUbgWxUOZvQuaja9SS1R2ZT3r1_Lypi6KZ4r755tKk8c74mhPPObF1r2C8qkctDb6QKfD5jze_9d7QXRsNBqZ0KamxycjI1OaHbKoxk0HUYeQsOEgHo4jJ4EZw5RgzBKc2QkjbpmEG4SGOLQwpWEecsIcc2jzeNxACPWCwd-zy8x1mDsTS6WXMq56GFubXVld-ckMYpWYEgd-RXs27c4sJpW6kEnOs8xqjBALWyaiCH0Dffyk4w
ContentType Journal Article
Copyright Copyright © Wanfang Data Co. Ltd. All Rights Reserved.
Copyright_xml – notice: Copyright © Wanfang Data Co. Ltd. All Rights Reserved.
DBID 2RA
92L
CQIGP
W91
~WA
2B.
4A8
92I
93N
PSX
TCJ
DOI 10.3760/cma.j.issn.0253-2727.2016.04.007
DatabaseName 维普期刊资源整合服务平台
中文科技期刊数据库-CALIS站点
维普中文期刊数据库
中文科技期刊数据库-医药卫生
中文科技期刊数据库- 镜像站点
Wanfang Data Journals - Hong Kong
WANFANG Data Centre
Wanfang Data Journals
万方数据期刊 - 香港版
China Online Journals (COJ)
China Online Journals (COJ)
DatabaseTitleList

DeliveryMethod fulltext_linktorsrc
DocumentTitleAlternate Comparison analysis of outcomes in primary light chain amyloidosis patients treated by auto peripheral blood stem cell transplantation or bortezomib plus dexamethasone
DocumentTitle_FL Comparison analysis of outcomes in primary light chain amyloidosis patients treated by auto peripheral blood stem cell transplantation or bortezomib plus dexamethasone
EndPage 287
ExternalDocumentID zhxyx201604007
668482373
GrantInformation_xml – fundername: 南京军区医学科技创新项目(10MA096) Medical Science and Technology Innovation Project of Nanjing Military Region
  funderid: (10MA096)
GroupedDBID ---
-05
2B.
2C~
2RA
92F
92I
92L
ACGFS
ALMA_UNASSIGNED_HOLDINGS
CCEZO
CIEJG
CQIGP
CW9
F5P
OK1
RPM
TCJ
TGQ
U1G
U5O
W91
~WA
4A8
93N
ABJNI
PSX
ID FETCH-LOGICAL-c587-e2f37f6691f3e9b3fd4aa47644adeacd1b826e1675e084779e5f9e4e0cebb1333
ISSN 0253-2727
IngestDate Thu May 29 04:03:11 EDT 2025
Wed Feb 14 10:20:12 EST 2024
IsPeerReviewed false
IsScholarly true
Issue 4
Keywords Immunoglobulin light chains
Retrospective studies
Bortezomib
硼替佐米
免疫球蛋白轻链
Amyloidosis
淀粉样变性
造血干细胞移植
回顾性研究
Hematopoietic stem cell transplantation
Language Chinese
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c587-e2f37f6691f3e9b3fd4aa47644adeacd1b826e1675e084779e5f9e4e0cebb1333
Notes Amyloidosis; Immunoglobulin light chains; Hematopoietic stem cell transplantation; Retrospective studies; Bortezomib
Zhao Qian, Wang Liping, Song Ping, Li Feng, Zhou Xiaogang, Yu Yaping, An Zhiming, Wang Xuli, Zhai Yongping.( Department of Hematology, Jinling Hospital, Nanjing 210002, China )
Objective To explore the feature of primary light chain amyloidosis patients treated with high-dose melphalan with auto peripheral blood stem cell transplantation (auto-PBSCT) and bortezomib plus dexamethasone (VD). Methods Thirty-eight patients diagnosed from September 2004 to September 2012 were analyzed retrospectively, including 15 cases received auto-PBSCT, 23 cases exposed with VD. Results The median follow-up duration for the patients was 34 months (range, 1-112 months), including auto-PBSCT group of 38 months (range, 5-112 months) and VD group of 31 months (range, 1-108 months). The organ response rate in all the patients was 39.5% (15/38), and the organ response rate between these two groups has no significant dif
PageCount 5
ParticipantIDs wanfang_journals_zhxyx201604007
chongqing_primary_668482373
PublicationCentury 2000
PublicationDate 2016
PublicationDateYYYYMMDD 2016-01-01
PublicationDate_xml – year: 2016
  text: 2016
PublicationDecade 2010
PublicationTitle 中华血液学杂志
PublicationTitleAlternate Chinese Journal of Hematology
PublicationTitle_FL Chinese Journal of Hematology
PublicationYear 2016
Publisher 210002,南京军区南京总医院血液科
Publisher_xml – name: 210002,南京军区南京总医院血液科
SSID ssj0042014
ssib051368330
ssib017477332
ssib001103535
ssib058574913
Score 2.054595
Snippet ...
目的 比较大剂量马法兰预处理的自体外周血造血干细胞移植(auto-PBSCT)与硼替佐米联合地塞米松(VD方案)治疗原发性轻链型淀粉样变性的疗效和安全性.方法 回顾性分析2004年9月至2012年9月38例原发性轻链型淀粉样变性患者的临床资料,其中auto-PBSCT组15例,VD组23例.结果...
SourceID wanfang
chongqing
SourceType Aggregation Database
Publisher
StartPage 283
SubjectTerms 免疫球蛋白轻链
回顾性研究
淀粉样变性
硼替佐米
造血干细胞移植
Title 自体外周血造血干细胞移植与硼替佐米联合地塞米松治疗原发性轻链型淀粉样变性的疗效和安全性比较
URI http://lib.cqvip.com/qk/93752X/201604/668482373.html
https://d.wanfangdata.com.cn/periodical/zhxyx201604007
Volume 37
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1JaxRBFG40gngRRUWNSw4WCMPEXms5ds_0IB48RcgtdM_0GAQnLhE0p0jUJLhrXHCJCQiKB5d4UImJfybdM_4L33u92Ki4wVBUv3r1va2661VTXaNpByKuZGC1o6ohQ70Kd6JRDbloVZtK6q12SzoqoF2-R_nhY_aRYWd4XZ9f2rV0bjwcbE788ruS_4kq0CCu-JXsP0S2AAUC1CG-UEKEofyrGDNfMljMuy7zbebVmbKY7zDXZopjRRnMlcjjGrihwVdYunqJ4jBPMc9kvmCexyQnQIspHykuEX2OgLJOIqA1bTKYV8Mm5TGvkUvXCQeaLMIxmLJJDZ1JSZUa80godE9FZMyAU2eejxVQBoUKNEEJZAaJqkGVBloEPGiFQBEgFJkVGo7dHYSVpLMnyECBgFKRFToSMxxZwgFZLpN2SSiUTq4zdK-Rzj7hAN0hrxbdAblBlkrUIf2_nDzdz5zm1qljnbxXOB-UJHsRvM5cnvlBEgW8qooUgbAd_KFfa-DICmorU2NJVVfl0bQquboesqP365Uc2ydvQTy9SmmEOBgXcAu2mcw1K6S3S-xUAQf9hK4KNQkch0ZZK_Kkmw8br05tyJ7G0sOBm2OWXz2l38Rmc5PpWFVTpMc65BNpenpP9sCwy7Ni5vsouxK_mrtxdxbccM2TweAJEjJYCMEdmHwwPef-e95S7CblXNp45pK1XttgCmE4P7y0gwzXcr6vCmANLkTp1D7HsLikPdZpAmeDNDp1Lhe_UTuY6XfoT9rhCS2jY53jpyHvpM8AO-2gc7yUsQ5t0TZnS80BN31ubNXWTYxu06Z706_WVu7Gz-_Ht1_2Fie_Ti5AGX9a6i5f6U3Nd18sJ8-vr3280V38nDz-srZyq_vufe_iXHxrJn7yNl6ch8vk6WqytNy9_yC-8Sy-eTuZfNFbWf56dzWev5p8mOwuzSYLH-KbD4HefXQJ2JJ7M_Gda_Hr2fjySyAmb-Z6q1PbtaGGP1Q7XM3-jKXadCAPicy2JdqcK6NtRSq02i07CGwBq6mgBblbywilySODCyfSIeEVKnLaKrIjvRmFoWFZ1g6trzPWiXZqA01wHNejUPAwtGFBqoTZagWw8ItsoxmEfJfWX_hw5FR65s5IEeNd2v7MqyPZk_jsyMTo-QvnMQqYkYjdv-3fr21CzvQt6h6tb_zMuWgvrCvGw300ar4BEhHwIQ
linkProvider National Library of Medicine
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=%E8%87%AA%E4%BD%93%E5%A4%96%E5%91%A8%E8%A1%80%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E4%B8%8E%E7%A1%BC%E6%9B%BF%E4%BD%90%E7%B1%B3%E8%81%94%E5%90%88%E5%9C%B0%E5%A1%9E%E7%B1%B3%E6%9D%BE%E6%B2%BB%E7%96%97%E5%8E%9F%E5%8F%91%E6%80%A7%E8%BD%BB%E9%93%BE%E5%9E%8B%E6%B7%80%E7%B2%89%E6%A0%B7%E5%8F%98%E6%80%A7%E7%9A%84%E7%96%97%E6%95%88%E5%92%8C%E5%AE%89%E5%85%A8%E6%80%A7%E6%AF%94%E8%BE%83&rft.jtitle=%E4%B8%AD%E5%8D%8E%E8%A1%80%E6%B6%B2%E5%AD%A6%E6%9D%82%E5%BF%97&rft.au=%E8%B5%B5%E8%8C%9C+%E7%8E%8B%E5%88%A9%E5%B9%B3+%E5%AE%8B%E8%90%8D+%E6%9D%8E%E9%94%8B+%E5%91%A8%E5%B0%8F%E9%92%A2+%E4%BA%8E%E4%BA%9A%E5%B9%B3+%E5%AE%89%E5%BF%97%E6%98%8E+%E7%8E%8B%E6%97%AD%E4%B8%BD+%E7%BF%9F%E5%8B%87%E5%B9%B3&rft.date=2016&rft.issn=0253-2727&rft.volume=37&rft.issue=4&rft.spage=283&rft.epage=287&rft_id=info:doi/10.3760%2Fcma.j.issn.0253-2727.2016.04.007&rft.externalDocID=668482373
thumbnail_s http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fimage.cqvip.com%2Fvip1000%2Fqk%2F93752X%2F93752X.jpg
http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fwww.wanfangdata.com.cn%2Fimages%2FPeriodicalImages%2Fzhxyx%2Fzhxyx.jpg